Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: RHOA activation is a critical event in the progression of BCR-FGFR1-driven leukemogenesis in stem cell leukemia and lymphoma syndrome and is regulated by the BCR GEF domain.
|
30413411 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCR-ABL1 oncogene is associated with chronic myeloid leukemia (CML) pathogenesis, but the molecular mechanisms that initiate leukemogenesis are still unclear.
|
30738963 |
2019 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The process of lymphomagenesis is multistep and encompasses mechanisms of antigen driven selection of the BCR with RF activity and various genetic contributors implicated in B cell proliferation, cell growth and cell cycle control, enhanced by a complex milieu of cytokines and trophic agents that are abundant within the inflammatory lesion of minor salivary glands of SS patients.
|
30572133 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Depending on the translocation breakpoint, typically a p210 BCR-ABL1 or a p190 BCR-ABL onc protein are generated; both are constitutively active tyrosine kinases that play a central role to alter signaling pathways of cell proliferation, survival, and self-renewal, leading to leukemogenesis.
|
28971501 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, in vivo engraftment studies demonstrated that manipulation of miR-17/92 was sufficient to affect BCR-FGFR1-driven leukemogenesis.
|
29367757 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis.We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation.
|
27821800 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that BTG1 deletions might play a role in leukemogenesis of BCP-ALL as well as of BCR-ABL1-positive MPAL and CML-BC (B-lineage).
|
24998463 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS mutations are overall rare in early phase CML and might be secondary events happening late in leukemogenesis cooperating with initial genetic lesions.
|
24377583 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altered expression of the anti-apoptoticBcl-xL has been correlated with BCR-ABL leukemogenesis; however, its involvement in the pathogenesis and evolution of CML has not been formally demonstrated yet.
|
23670294 |
2013 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
|
23894305 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid leukemia (CML), characterized by the t(9;22) and BCR/ABL1 fusion, is a disease model for studying the mechanisms of genetic abnormalities in leukemogenesis.
|
22118744 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that FANCD2-Ub has an important role in BCR-ABL1 leukemogenesis because of its ability to facilitate the repair of numerous ROS-induced DSBs.
|
21519342 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other translocations interrupting the 6q22-q23 breakpoint cluster region did not appear to be recurrent and may contribute to leukemogenesis through a novel mechanism.
|
15921375 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The absence of differences between the patients with and without 3' BCR deletion supports the hypothesis that the hybrid gene ABL-BCR does not have an important role in leukemogenesis in CML cases.
|
11672777 |
2001 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of normal ABL and BCR and of reciprocal fusion genes BCR-ABL and ABL-BCR was examined in a panel of 53 BCR-ABL-positive cell lines by RT-PCR to determine the influence of the various transcripts on leukemogenesis.
|
10576511 |
1999 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support the concept that the BCR-ABL chimeric gene plays a crucial role in leukemogenesis but suggest that factors other than the position of the breakpoint in the BCR gene determine the lineage of the target cell for malignant transformation.
|
3179449 |
1988 |